2Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 1998, 339: 61-68.
3Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
4Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2001, 34:1225-1241.
5Kobayashi S, Ide T, Sata M, et al. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol, 2001, 34: 584-586.
6Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002,37: 259-265.
2Sanchez Tapias JM,Costa J,Mas A,Bruguera M,Rodes J,Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients[J].Gastroenterology,2002,123(6):1848-1856.
3Wai CT,Chu CJ,Hussain M,Lok AS.HBV genotype B is associated with better response to interferon therapy in HBeAg(+)chronic hepatitis than genotype C[J].Hepatology,2002,36(6):1425-1430.
4Kao JH,Liu CJ,Chen DS.Hepatitis B viral genotypes and lamivudine resisitance[J].J Hepatol,2002,36:303-304.
